Alnylam Pharmaceuticals PE Ratio 2006-2021 | ALNY

Current and historical p/e ratio for Alnylam Pharmaceuticals (ALNY) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Alnylam Pharmaceuticals PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Alnylam Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 198.61 0.00
2021-06-30 169.52 $-7.59 0.00
2021-03-31 141.19 $-7.54 0.00
2020-12-31 129.97 $-7.45 0.00
2020-09-30 145.60 $-7.83 0.00
2020-06-30 148.11 $-7.57 0.00
2020-03-31 108.85 $-8.03 0.00
2019-12-31 115.17 $-8.14 0.00
2019-09-30 80.42 $-7.76 0.00
2019-06-30 72.56 $-8.27 0.00
2019-03-31 93.45 $-7.88 0.00
2018-12-31 72.91 $-7.56 0.00
2018-09-30 87.52 $-6.95 0.00
2018-06-30 98.49 $-5.86 0.00
2018-03-31 119.10 $-5.57 0.00
2017-12-31 127.05 $-5.41 0.00
2017-09-30 117.49 $-5.25 0.00
2017-06-30 79.76 $-5.12 0.00
2017-03-31 51.25 $-4.83 0.00
2016-12-31 37.44 $-4.79 0.00
2016-09-30 67.78 $-4.54 0.00
2016-06-30 55.49 $-4.24 0.00
2016-03-31 62.77 $-4.04 0.00
2015-12-31 94.14 $-3.45 0.00
2015-09-30 80.36 $-2.66 0.00
2015-06-30 119.87 $-2.33 0.00
2015-03-31 104.42 $-2.06 0.00
2014-12-31 97.00 $-5.14 0.00
2014-09-30 78.10 $-5.37 0.00
2014-06-30 63.17 $-5.27 0.00
2014-03-31 67.14 $-4.98 0.00
2013-12-31 64.30 $-1.43 0.00
2013-09-30 64.01 $-2.12 0.00
2013-06-30 31.00 $-2.02 0.00
2013-03-31 24.37 $-1.98 0.00
2012-12-31 18.25 $-2.08 0.00
2012-09-30 18.79 $-1.21 0.00
2012-06-30 11.65 $-1.14 0.00
2012-03-31 11.07 $-1.22 0.00
2011-12-31 8.15 $-1.35 0.00
2011-09-30 6.57 $-1.18 0.00
2011-06-30 9.37 $-1.10 0.00
2011-03-31 9.56 $-1.12 0.00
2010-12-31 9.86 $-1.03 0.00
2010-09-30 12.27 $-1.06 0.00
2010-06-30 15.02 $-1.05 0.00
2010-03-31 17.02 $-1.25 0.00
2009-12-31 17.62 $-1.15 0.00
2009-09-30 22.68 $-1.19 0.00
2009-06-30 22.27 $-1.04 0.00
2009-03-31 19.04 $-0.80 0.00
2008-12-31 24.73 $-0.64 0.00
2008-09-30 28.95 $-0.37 0.00
2008-06-30 26.73 $-1.65 0.00
2008-03-31 24.40 $-1.68 0.00
2007-12-31 29.08 $-2.23 0.00
2007-09-30 32.77 $-2.53 0.00
2007-06-30 15.19 $-1.41 0.00
2007-03-31 18.00 $-1.38 0.00
2006-12-31 21.40 $-1.10 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $23.604B $0.493B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76